- Home
- ONTF vs TVRD Comparison
ONTF vs TVRD Comparison
Compare ONTF & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONTF
- TVRD
- Stock Information
- Founded
- ONTF 1998
- TVRD 2017
- Country
- ONTF United States
- TVRD United States
- Employees
- ONTF N/A
- TVRD N/A
- Industry
- ONTF Computer Software: Prepackaged Software
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- ONTF Technology
- TVRD Health Care
- Exchange
- ONTF Nasdaq
- TVRD Nasdaq
- Market Cap
- ONTF 230.2M
- TVRD 246.5M
- IPO Year
- ONTF 2021
- TVRD N/A
- Fundamental
- Price
- ONTF $5.56
- TVRD $28.05
- Analyst Decision
- ONTF Hold
- TVRD Strong Buy
- Analyst Count
- ONTF 4
- TVRD 5
- Target Price
- ONTF $5.33
- TVRD $59.20
- AVG Volume (30 Days)
- ONTF 162.1K
- TVRD 23.9K
- Earning Date
- ONTF 08-07-2025
- TVRD 08-14-2025
- Dividend Yield
- ONTF N/A
- TVRD N/A
- EPS Growth
- ONTF N/A
- TVRD N/A
- EPS
- ONTF N/A
- TVRD N/A
- Revenue
- ONTF $143,071,000.00
- TVRD N/A
- Revenue This Year
- ONTF N/A
- TVRD N/A
- Revenue Next Year
- ONTF N/A
- TVRD N/A
- P/E Ratio
- ONTF N/A
- TVRD N/A
- Revenue Growth
- ONTF N/A
- TVRD N/A
- 52 Week Low
- ONTF $4.35
- TVRD $8.13
- 52 Week High
- ONTF $7.04
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- ONTF 63.62
- TVRD 62.10
- Support Level
- ONTF $5.16
- TVRD $22.91
- Resistance Level
- ONTF $5.38
- TVRD $27.25
- Average True Range (ATR)
- ONTF 0.19
- TVRD 1.63
- MACD
- ONTF 0.06
- TVRD 0.36
- Stochastic Oscillator
- ONTF 98.81
- TVRD 86.79
About ONTF ON24 Inc.
ON24 Inc provides a cloud-based intelligent engagement platform that combines experiences with personalization and content, to enable sales and marketing organizations to capture and act on connected insights at scale. The Company's platform offers a portfolio of interactive and hyper-personalized digital experience products that create and capture actionable, real-time data at scale from millions of professionals to provide businesses with buying signals and behavioral insights to efficiently convert prospects into customers. It provides solutions to Financial services, Life Sciences, Life sciences, Insurance, Technology, Associations, and Others.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.